TherapeuticsMD (TXMD) Given a $14.00 Price Target by Oppenheimer Analysts

Share on StockTwits

Oppenheimer set a $14.00 target price on TherapeuticsMD (NASDAQ:TXMD) in a research report sent to investors on Wednesday morning. The firm currently has a buy rating on the stock.

Several other analysts have also issued reports on TXMD. BidaskClub upgraded shares of TherapeuticsMD from a strong sell rating to a sell rating in a research note on Wednesday, August 29th. Zacks Investment Research upgraded shares of TherapeuticsMD from a sell rating to a hold rating in a research note on Saturday, August 25th. ValuEngine upgraded shares of TherapeuticsMD from a hold rating to a buy rating in a research note on Tuesday, May 8th. Finally, JPMorgan Chase & Co. set a $11.00 target price on shares of TherapeuticsMD and gave the stock a buy rating in a research note on Wednesday, August 15th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $14.00.

NASDAQ TXMD opened at $6.36 on Wednesday. TherapeuticsMD has a 1 year low of $4.34 and a 1 year high of $7.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 7.88 and a quick ratio of 7.79. The firm has a market capitalization of $1.50 billion, a PE ratio of -17.19 and a beta of 1.55.

TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Monday, July 30th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.03). TherapeuticsMD had a negative return on equity of 80.75% and a negative net margin of 582.86%. The firm had revenue of $3.80 million during the quarter, compared to the consensus estimate of $4.23 million. During the same quarter in the previous year, the company earned ($0.10) EPS. The business’s revenue was down 11.6% compared to the same quarter last year. analysts forecast that TherapeuticsMD will post -0.63 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. grew its position in TherapeuticsMD by 4.4% during the second quarter. BlackRock Inc. now owns 14,533,524 shares of the company’s stock valued at $90,690,000 after buying an additional 608,470 shares during the period. Voya Investment Management LLC grew its position in TherapeuticsMD by 7.7% during the second quarter. Voya Investment Management LLC now owns 3,419,174 shares of the company’s stock valued at $21,336,000 after buying an additional 242,995 shares during the period. OppenheimerFunds Inc. grew its position in TherapeuticsMD by 17.4% during the second quarter. OppenheimerFunds Inc. now owns 1,932,439 shares of the company’s stock valued at $12,058,000 after buying an additional 286,123 shares during the period. Stifel Financial Corp grew its position in TherapeuticsMD by 1.3% during the first quarter. Stifel Financial Corp now owns 1,862,644 shares of the company’s stock valued at $9,067,000 after buying an additional 23,141 shares during the period. Finally, First Eagle Investment Management LLC grew its position in TherapeuticsMD by 11.4% during the first quarter. First Eagle Investment Management LLC now owns 1,747,336 shares of the company’s stock valued at $8,510,000 after buying an additional 179,244 shares during the period. Institutional investors own 66.14% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Recommended Story: Short Selling

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply